Recently, Professor Federica Sotgia and Professor Michael Lisanti made a discovery that could make cancer a treatable ailment.
For many years, billions of dollars have been poured into the field of cancer research in an effort to find ways to treat and cure the disease. However, there are still no FDA/MHRA approved drugs that combat metastasis. As a result, cancer metastasis, which is lethal, remains an untreatable and mysterious disease.
For those who may not be completely familiar with cancer metastasis; this is when cancer cells spread throughout the body’s organs such as the lungs, bone tissue, the brain and the liver. Metastasis turns the cancer into a terminal illness that it untreatable as there are no effective therapies that are available.
When the cancer is present in other organs and tumors have grown in those organs, doctors may advise for tumor removal, depending on your cancer’s progress and treatment procedure. Usually, after the primary tumor has been surgically removed, many cancer patients undergo radiation and chemotherapy to eliminate the remaining tumor cells that may have remained in the body. Unfortunately, most cancer patients experience tumor recurrence, which results in the cancer spreading.
Consequently, more than 90% of these cancer patients who experience treatment failure lose their lives to metastatic disease. Now researchers at the University of Salford have discovered that ATP-depletion is the weakness of metastasis. This depletion can be accomplished by removing the cancer cell’s capacity to make new energy.
Therefore, the discovery by Professor Federica Sotgia and Professor Michael Lisanti of metastasis inhibitors that could turn cancer into a chronic disease that is treatable is a remarkable feat. Both professors, who work at the University of Salford in Translational Medicine, have created and evaluated new cancer metastasis inhibitors which are based on Doxycycline, which is an FDA-approved antibiotic that was first approved in 1967.
They chemically modified Doxycycline, making it 5 times more powerful in attacking metastatic cancer cells. This modification to the Doxycycline antibiotic also renders it ineffective when used as an antibiotic, which effectively eliminates the risk of developing antibiotic resistant infections and bacteria.
Additionally, Doxy-Myr, the new modified drug, has an added fatty acid that is non-toxic, as seen in pre-clinical studies. While clinical trials are being conducted to determine the efficacy of this drug in helping prevent metastasis as well as help design drugs that will prevent metastasis, this breakthrough could change how cancer is treated. The addition of metastasis prevention as an effective way to treat cancer shows incredible progress in cancer research.
Analysts believe that is discovery is likely to be of great interest to lots of biomedical companies like 180 Life Sciences Corp.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Researchers at the University of Virginia have conducted a study that offers new insights into…
Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no…
The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and…
Unlike prostate, colon and breast cancers, the screening for lung cancer hasn’t been very successful. This is largely because screening focuses…
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio…
As the cost of health care skyrockets across the U.S., residents in many states are…